Inhibition of human prostate cancer cells proliferation by a selective alpha1-adrenoceptor antagonist labedipinedilol-A involves cell cycle arrest and apoptosis

Toxicology

Volumn 256, Issue 1-2, 2009, Pages 13-24

  Liou, Shu Fen ^a   Lin, Hung Hong ^a   Liang, Jyh Chong ^b   Chen, Ing Jun ^c   Yeh, Jwu Lai ^c  

^a CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^b CHIN MIN INSTITUTE OF TECHNOLOGY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

1 Adrenoceptor antagonist; Anti proliferation; Apoptosis; Cell cycle; Prostate cancer

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYTOCHROME C; HOE 33342; LABEDIPINEDILOL A; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NORADRENALIN; PROTEIN BAX; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ADRENERGIC ALPHA-ANTAGONISTS; ANISOLES; APOPTOSIS; BENZIMIDAZOLES; BLOTTING, WESTERN; CASPASE 3; CASPASE 9; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DIHYDROPYRIDINES; FLUORESCENT DYES; HUMANS; MALE; MEMBRANE POTENTIALS; MITOCHONDRIAL MEMBRANES; MITOGEN-ACTIVATED PROTEIN KINASES; ONCOGENE PROTEIN V-AKT; PROSTATIC NEOPLASMS; RECEPTORS, ADRENERGIC, ALPHA-1; SIGNAL TRANSDUCTION;

EID: 58149234675     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2008.10.025     Document Type: Article

References (45)

1. Adhami V.M., Aziz M.H., Reagan-Shaw S.R., Nihal M., Mukhtar H., and Ahmad N. Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. Mol. Cancer Ther. 3 8 (2004) 933-940
2. Berges R.R., Vucanovic J., Epstein J.I., Walsh P.C., and Isaacs J.T. Implication of cell cycle changes during the progression of human prostate cancer. Clin. Cancer Res. 1 5 (1995) 473-480
3. Bonni A., Brunet A., West A.E., Datta S.R., Takasu M.A., and Greenberg M.E. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286 5443 (1999) 1358-1362
4. Bruckheimer E.M., and Kyprianou N. Apoptosis in prostate carcinogenesis: a growth regulator and a therapeutic target: a review. Cell Tissue Res. 301 1 (2000) 153-162
5. Carson C.C. Carcinoma of the prostate: overview of the most common malignancy in men. N. C. Med. J. 67 2 (2006) 122-127
6. Craft N., Shostak Y., Carey M., and Sawyers C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5 3 (1999) 280-285
7. Garrison J.B., and Kyprianou N. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res. 66 1 (2006) 464-472
8. Gioeli D., Mandell J.W., Petroni G.R., Frierson, and Weber M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59 2 (1999) 279-284
9. Gleave M., Bruchovsky N., Goldenberg S.L., and Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Eur. Urol. 34 3 (1998) 37-41
10. Graff J.R., Konicek B.W., McNulty A.M., Wang Z., Houck K., Allen S., Paul J.D., Hbaiu A., Goode R.G., Sandusky G.E., Vessella R.L., and Neubauer B.L. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem. 275 32 (2000) 24500-24505
11. Grana X., and Reddy P. Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CDKIs). Oncogene 11 2 (1995) 211-219
12. Hajra K.M., and Liu J.R. Apoptosome dysfunction in human cancer. Apoptosis 9 6 (2004) 691-704
13. Hampel C., Dolber P.C., Smith M.P., Savic S.L., Throff J.W., Thor K.B., and Schwinn D.A. Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. J. Urol. 167 3 (2002) 1513-1521
14. Hengartner M.O. The biochemistry of apoptosis. Nature 407 6805 (2000) 770-776
15. Herr I., and Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood 98 9 (2001) 2603-2614
16. Hunter T. Braking the cycle. Cell 75 5 (1993) 839-841
17. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics. CA Cancer J. Clin. 56 2 (2006) 106-130
18. Kanagawa K., Sugimura K., Kuratsukuri K., Ikemoto S., Kishimoto T., and Nakatani T. Norepinephrine activates p44 and p42 MAPK in human prostate stromal and smooth muscle cells but not in epithelial cells. Prostate 56 4 (2003) 313-318
19. Kanda H., Ishii K., Ogura Y., Imamura T., Kanai M., Arima K., and Sugimura Y. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. Int. J. Cancer 122 2 (2008) 444-451
20. Keledjian K., Garrison J.B., and Kyprianou N. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J. Cell. Biochem. 94 2 (2005) 374-388
21. Kyprianou N., and Benning C.M. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res. 60 16 (2000) 4550-4555
22. Liou S.F., Yeh J.L., Liang J.C., Chiu C.C., Lin Y.T., and Chen I.J. Inhibition of mitogen-mediated proliferation of rat vascular smooth muscle cells by labedipinedilol-A through PKC and ERK 1/2 pathway. J. Cardiovasc. Pharmacol. 44 5 (2004) 539-551
23. McVary K.T., McKenna K.E., and Lee C. Prostate innervation. Prostate 8 Suppl. (1998) 2-13
24. Michel M.C., and Vrydag W. Alpha1-, alpha2-and beta-adrenoceptors in the urinary bladder, urethra and prostate: more than smooth muscle relaxation?. Br. J. Pharmacol. 147 Suppl. 2 (2006) S88-S119
25. Millikan R.E. Chemotherapy of advanced prostatic carcinoma. Semin. Oncol. 26 2 (1999) 185-191
26. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., Loh D.Y., and Nakayama K. Mice lacking p27 (Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85 5 (1996) 707-720
27. Pavletich N.P. Mechanisms of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and CIP and INK4 inhibitors. J. Mol. Biol. 287 5 (1999) 821-828
28. Price D.T., Rocca G.D., Guo C., Ballo M.S., Schwinn D.A., and Luttrell L.M. Activation of extracellular signal-regulated kinase in human prostate cancer. J. Urol. 162 4 (1999) 1537-1542
29. Quaglia W., Santoni G., Pigini M., Piergentili A., Gentili F., Buccioni M., Mosca M., Lucciarini R., Amantini C., Nabissi M.I., Ballarini P., Poggesi E., Leonardi A., and Giannella M. Structure-activity relationships in 1,4-benzodioxan-related compounds.8.(1){2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation. J. Med. Chem. 48 24 (2005) 7750-7763
30. Roehrborn C.G., and Schwinn D.A. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J. Urol. 171 3 (2004) 1029-1035
31. Roy A.M., Baliga M.S., Elmets C.A., and Katiyar S.K. Grape seed proanthocyanidins induce apoptosis through p53, Bax, and caspase-3 pathways. Neoplasia 7 1 (2005) 24-36
32. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60 14 (2000) 3689-3695
33. Sherr C.J., and Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9 10 (1995) 1149-1163
34. Shimada K., Nakamura M., Ishida E., Kishi M., and Konishi N. Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 24 6 (2003) 1067-1075
35. Sivaraman V.S., Wang H., Nuovo G.J., and Malbon C.C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest. 99 7 (1997) 1478-1483
36. Stabile E., Zhou Y.F., Saji M., Castagna M., Shou M., Kinnaird T.D., Baffour R., Ringel M.D., Epstein S.E., and Fuchs S. Akt controls vascular smooth muscle cell proliferation in vitro and in vivo by delaying G1/S exit. Circ. Res. 93 11 (2003) 1059-1065
37. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., Mangion J., Jacotot E., Costantini P., Loeffler M., Larochette N., Goodlett D.R., Aebersold R., Siderovski D.P., Penninger J.M., and Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factors. Nature 397 6718 (1999) 441-446
38. Tang D.G., and Porter A.T. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 32 4 (1997) 284-293
39. 2/M transition by p53. Oncogene 20 15 (2001) 1803-1815
40. 2+-permeable cationic channels in prostate cancer epithelial cells. J. Clin. Invest. 111 11 (2003) 1691-1701
41. Walden P.D., Gerardi C., and Lepor H. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J. Urol. 161 2 (1999) 635-640
42. Waxman D.J., and Schwartz P.S. Harnessing apoptosis for improved anticancer gene therapy. Cancer. Res. 63 24 (2003) 8563-8572
43. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 81 3 (1995) 323-330
44. Xin X., Yang N., Eckhart A.D., and Faber J.E. Alpha1D-adrenergic receptors and mitogen-activated protein kinase mediate increased protein synthesis by arterial smooth muscle. Mol. Pharmacol. 51 5 (1997) 764-775
45. Zhuang S., and Schnellmann R.G. A death-promoting role for extracellular signal-regulated kinase. J. Pharmacol. Exp. Ther. 319 3 (2006) 991-997